Kletzky O A, Vermesh M
Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles.
Fertil Steril. 1989 Feb;51(2):269-72. doi: 10.1016/s0015-0282(16)60489-2.
Treatment of hyperprolactinemia with oral bromocriptine has been associated with a high incidence of side effects. The authors recently demonstrated that, in normal women, the vaginal route of administration was an effective and safe alternative to oral bromocriptine. To evaluate the effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia, the authors treated 15 hyperprolactinemic women with daily vaginal administration of 2.5 mg tablets of bromocriptine. Serum prolactin (PRL) levels and vital signs were measured daily for 6 days, then weekly for 4 weeks. Gastrointestinal side effects were limited to a single episode of mild nausea, and two cases of transient constipation. In all patients there was a dramatic initial reduction in PRL in response to a single 2.5 mg dose of bromocriptine. In 13 patients PRL levels were maintained within the normal range with daily administration of 2.5 mg, whereas in two patients, PRL levels remained higher than normal despite an increase in bromocriptine dose to 5 mg. These results suggest that short term use of vaginal bromocriptine is a safe and effective method of therapy for hyperprolactinemia.
口服溴隐亭治疗高催乳素血症与副作用的高发生率相关。作者最近证明，在正常女性中，阴道给药途径是口服溴隐亭的一种有效且安全的替代方法。为评估阴道用溴隐亭治疗高催乳素血症女性的有效性，作者对15名高催乳素血症女性进行治疗，每日经阴道给予2.5毫克溴隐亭片剂。连续6天每日测量血清催乳素（PRL）水平和生命体征，然后连续4周每周测量一次。胃肠道副作用仅限于单次轻度恶心发作和两例短暂便秘。所有患者单次给予2.5毫克溴隐亭后，PRL均出现显著的初始降低。13名患者每日给予2.5毫克时PRL水平维持在正常范围内，而两名患者尽管溴隐亭剂量增加至5毫克，PRL水平仍高于正常。这些结果表明，短期使用阴道用溴隐亭是治疗高催乳素血症的一种安全有效的方法。
